HydraFacial vs. BioRePeel: What You’re Actually Buying

These two get presented as rungs on a ladder — HydraFacial as the entry point, BioRePeel as the upgrade for people who’ve outgrown it. That’s a sales structure, not a clinical one. They do different things, the evidence behind them is very differently sized, and one of them has a detail in its history that I think every patient should know before booking.

We sell both. Read accordingly.

What actually happens during a HydraFacial?

A spiral tip does three things in one pass: exfoliates the surface, applies gentle vacuum suction to clear pores, and infuses serums into skin that’s just been cleaned. No abrasive crystals, no acid burn, no recovery.

That’s it. It’s a very well-engineered version of a facial, and I mean that as a compliment rather than a dismissal — the standardisation is the point. A HydraFacial delivered by two different providers is far more alike than two hand-performed facials would be.

Is there real evidence behind it?

More than I expected, and less than the marketing implies.

The foundational work is histological. Freedman’s controlled study in the Journal of Cosmetic Dermatology compared hydradermabrasion with an antioxidant serum against manual application of the same serum, six treatments at 7–10 day intervals. The treated group showed increased epidermal thickness, increased papillary dermal thickness and higher polyphenolic antioxidant levels, all at p < 0.01, with replacement of elastotic dermal tissue, collagen hyalinization and greater fibroblast density — alongside reduced fine lines, pore size and hyperpigmentation. The manual-serum group showed no change in skin structure, antioxidant levels or clinical attributes.

That last sentence is the important one. The delivery mechanism does something that rubbing the same serum on your face does not.

For acne, there’s a 2022 study in the Journal of Clinical and Aesthetic Dermatology: 20 patients, ages 19 to 48, six treatments over 12 weeks. Overall skin appearance improved in patients with active acne.

Fact vs. Fad: Twenty patients, no control group, and the study was tied to the device company. That doesn’t make it worthless — it was published in a peer-reviewed journal and it’s more than most facial treatments can show — but “clinically proven” is heavier language than 20 uncontrolled patients can carry. The broader literature reflects the same gap: for a treatment this popular, studies validating it against objective histological measures remain scarce.

Where that leaves me: HydraFacial is a genuine maintenance treatment with real mechanistic support and modest clinical evidence. It is not going to fix sun damage, acne scarring or laxity, and a practice implying otherwise is overselling a good product.

What is BioRePeel, and is it really a “medical device”?

BioRePeel is a trichloroacetic acid peel with an unusual delivery system. Two phases: a lipophilic layer that slows and buffers penetration, and a hydrophilic layer carrying the actives — TCA plus lactobionic, salicylic, tartaric and citric acids, GABA, amino acids including glycine, proline, hydroxyproline and arginine, and vitamins C and B2.

The biphasic design is a legitimate piece of formulation engineering. Buffering how fast an acid reaches tissue is a real way to change its behaviour.

Now the regulatory point, which matters. BioRePeel is described as a medical device — and it is, in Europe, where it carries a CE mark under the EU device framework. That designation is European. It is not an FDA clearance or approval, and in the United States the product sits in a different regulatory position entirely.

This is the third time in as many articles I’ve run into the same pattern: a real credential from one jurisdiction or one product being carried across to imply something it doesn’t cover. It’s worth learning to spot. When you see “medical device” or “FDA-approved,” the question to ask is approved by whom, and for what exactly.

Why was the US concentration lowered to 30%?

Here’s the detail I’d want to know as a patient.

There are two products with nearly the same name. BioRePeelCl3 FND is the European formulation for face, neck and décolleté, and it contains 35% TCA. BioRePeelCl3 Blue is the US product for the same areas — and in July 2023 it was modified to 30% modulated TCA.

The reason given publicly by David Burke of BioSkin Aesthetics, the US distributor, was that the change came after months of testing to ensure quality was not sacrificed, and that it “allowed several estheticians to be within the scope of their practice.”

Read that again. The concentration of the acid in the American product was adjusted, at least in part, so that the people applying it would be legally permitted to apply it.

The product we use is that US Blue formulation, at 30%.

I want to be fair about this. It is not evidence the product is unsafe — arguably the opposite, since it’s a company matching its formulation to who will realistically be using it, which is a responsible thing to do. And 30% TCA is still a serious acid.

But it tells you something about how this category works. The strength of what goes on your face was set partly by scope-of-practice law, not purely by what the skin in front of the provider needed. That’s a legitimate constraint. It’s just not the story the marketing tells, and you’re entitled to know it before you decide who should be doing your peel.

Is it really a peel with no peeling?

Partly. TCA at 30% is a serious agent, and the biphasic delivery genuinely does moderate the immediate reaction — most people don’t get the frosting or sheet peeling a traditional TCA application would produce.

But “no downtime” is doing work. Expect tightness, some dryness, and light flaking over the following days, more so if you go deeper or stack sessions. I’d rather you plan for a few unglamorous days and be pleasantly surprised than book one before an event on the strength of a marketing phrase.

The honest evidence position is thinner than for HydraFacial. Independent, peer-reviewed clinical trials of this specific product are scarce; most of what circulates is manufacturer material and clinic testimonial. The individual acids in it are well studied. The proprietary combination, in this delivery system, largely isn’t.

So which should you book?

Not a ladder. Two different jobs.

HydraFacial is maintenance. Deep cleansing, hydration, immediate glow, no recovery, safe on essentially any skin. Monthly, or before an event. It manages skin; it doesn’t remodel it.

BioRePeel is a corrective treatment. It’s for texture, congestion, early pigment and acne-prone skin, in a short series, with a few days of mild flaking as part of the deal. It changes things HydraFacial won’t touch. It also isn’t the only peel on our menu — a VI Peel is the other, and which of the two suits your skin is a consultation question.

Plenty of patients do both — a peel series a few times a year, HydraFacial in between. That’s not upselling; the two occupy genuinely different places in a plan.

And if what’s actually bothering you is sun damage, real acne scarring or laxity, neither of these is your answer. That’s a laser or an energy-device conversation — LaseMD Ultra or Morpheus8 — and I’d rather redirect you than sell you six facials.

Both treatments here are performed by our licensed medical aestheticians. I’d rather state that plainly than let you assume a physician is doing your facial.

References

Freedman BM. Hydradermabrasion: an innovative modality for nonablative facial rejuvenation. Journal of Cosmetic Dermatology. 2008;7(4):275–280. doi:10.1111/j.1473-2165.2008.00406.x (controlled split comparison)

Storgard R, Mauricio-Lee J, Mauricio T, Zaiac M, Karnik J. Efficacy and tolerability of HydraFacial Clarifying Treatment series in the treatment of active acne vulgaris. Journal of Clinical and Aesthetic Dermatology. 2022;15(12):42–46. (open-label, uncontrolled, n=20; one author employed by the device company)

BioSkin Aesthetics (US distributor). BioRePeelCl3 BLUE product information: 30% trichloroacetic acid, two-phase topical peel for face, neck and décolleté. Reformulation statement attributed to David Burke, July 2023.

CMed Aesthetics S.p.A. BioRePeelCl3 FND product information: 35% trichloroacetic acid, two-phase topical medical device. Manufacturer materials, accessed August 2026.